Institutional investors hold a majority ownership of MYGN through the 128.44% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2016, these large investors purchased a net $3.0 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CAMBER CAPITAL MANAGEMENT LLC Bought 3.8 Million shares of Myriad Genetics Inc
ACADIAN ASSET MANAGEMENT LLC Bought 2.3 Million shares of Myriad Genetics Inc
RENAISSANCE TECHNOLOGIES LLC Bought 1.6 Million shares of Myriad Genetics Inc